Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$564K, compared with $3.05M a year earlier. Trailing-twelve-month other income / expenses was $745K. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$564K or moves back toward the trailing-twelve-month quarterly average of $186.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 4.36M USD
- Year-over-year change
- -78.1%
- 4-year CAGR
- +346.1%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.36M | -78.1% |
| FY2024 | 2024-12-31 | 19.86M | +141.8% |
| FY2023 | 2023-12-31 | (47.46M) | -1055.8% |
| FY2022 | 2022-12-31 | 4.97M | +45045.5% |
| FY2021 | 2021-12-31 | 11K | — |
Other Income / Expenses vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 other income / expenses of $745K is the 7th highest of the 10 companies compared; the peer median is $18.29M.
- Its year-over-year change of -95.5% is the 8th highest of 10, against a peer median of -30.6%.
- Over three fiscal years its annual growth of -4.3% compares with a peer median of +113.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $191.32M | +1815.8% | — | 1933.9% | |
| LTM Mar 2026 | $24.78M | -37.5% | +128.9% | 39.0% | |
| LTM Mar 2026 | $20.28M | -10.8% | — | 35.0% | |
| LTM Mar 2026 | $18.65M | -30.6% | +97.1% | 21.1% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $18.29M | -91.0% | +350.3% | 247.2% |
| LTM Mar 2026 | $10.44M | -12.7% | +54.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Mar 2026 | -$1.86M | -1250.0% | — | 2.7% | |
| LTM Mar 2026 | -$17.66M | +27.0% | — | 22.3% | |
| LTM Mar 2026 | -$23.51M | -111.8% | — | 25.4% | |
| Peer median (excluding NMRA) | $18.29M | -30.6% | +113.0% | 30.2% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| Weighted Avg Shares | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
| Weighted Avg Shares (Diluted) | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.